(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Dozens injured in Russia after train crashes, overturns - 2Inside The Design-Forward Wellness Hotel Marking A New Chapter In Medellín
- 3the Kinds of Thailand: Decision in favor of Your Number one Thai Dish!
- 4Picking the Right Home Machines: A Commonsense Aide
- 5Vote in favor of your Number one Sort of Cap
- Iran, Hezbollah fire rockets at Israel during Passover celebrations
- Russia Establishing Long-Range Drone Bases In Belarus, Warns Ukraine
- Can scientists detect life without knowing what it looks like? Research using machine learning offers a new way
- Tesla plans to expand production at German car plant
- Antimatter took to the road for the very first time. Here’s why it matters
- Vote in favor of Your #1 Instructive Toy: Learning and Tomfoolery Joined
- What's A Decent FICO rating?
- It's official: NASA's Artemis 2 moon mission will break humanity's all-time distance record
- Canada's Friendly Sunshine Coast City Is An Outdoor Playground Perfect For Hiking And Paddling
